Don't Get Blindsided by Emerging Targets
Imalumab is the only drug targeting oxMIF to reach #clinicaltrials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they have invested in three different modalities targeting oxMIF via distinct mechanisms of action, see link below.
Through #aitechnology, Kognitic’s platform will automatically capture the emergence of assets directed at this under-the-radar target and details of their clinical trials, such as other drugs/targets they’re combining with, relevant patient segmentations, and critical events for those trials. Clients leveraging #Kognitic’s platform will be first to know if these assets are doomed to the same fate as imalumab, or if in oxMIF lies an investment opportunity.